Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period

Effectiveness of AZD7442 (Tixagevimab/Cilgavimab) for Pre-Exposure Prophylaxis Against COVID-19 Hospitalization in Israel During the Omicron Sub-Variant Time Period

Abstract Introduction The effectiveness of AZD7442 (tixagevimab/cilgavimab) against COVID-19 hospitalizations was determined at 3 and 6 months among immunocompromised individuals in Israel during different variant circulations. Methods This was a retrospective cohort study using data from Clalit Hea...

Full description

Saved in:
Bibliographic Details
Main Authors: Samah Hayek, Joseph Levy, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, Sabada Dube, Cátia Ferreira, Idit Livnat, Carla Talarico, Sylvia Taylor, Sudhir Venkatesan, Adva Yarden, Ran D. Balicer, Doron Netzer, Alon Peretz
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-01-01
Series:Infectious Diseases and Therapy
Subjects:
AZD7442
COVID-19
Effectiveness
Immunocompromised
Monoclonal antibodies
Online Access:https://doi.org/10.1007/s40121-024-01100-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40121-024-01100-3

Similar Items